Stay updated on Pembrolizumab for Cancer of Unknown Primary Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the CUPem pembrolizumab trial is displayed, with study details and supporting materials available in place of the access-denied page.
    Difference
    59%
    Check dated 2026-11-08T13:42:32.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0, while the study record remains unavailable.
    Difference
    0.2%
    Check dated 2026-11-01T14:57:40.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A site-wide notice announces an NIH website transition and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence.” The study record remains unavailable behind a 403 error.
    Difference
    1%
    Check dated 2026-10-25T15:48:10.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The page no longer displays a 403 error and instead shows the ClinicalTrials.gov site shell, with an updated revision label. The study record content is not visible.
    Difference
    0.8%
    Check dated 2026-10-18T16:35:24.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T16:12:25.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error page, blocking access to the study record content. The additions include the 403 message and standard site header/footer, indicating restricted access to the content.
    Difference
    20%
    Check dated 2026-09-20T22:34:22.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Cancer of Unknown Primary Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.